Drug intelligence / Profile preview

gallium Ga-68 exendin

Development stage: Unknown
Lead developer: Radboud University Medical Center
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
Administration: Intravenous

Overview

Gallium Ga-68 exendin (specifically gallium Ga-68 exendin-4) is a diagnostic radiopharmaceutical PET imaging tracer targeting the glucagon-like peptide-1 receptor (GLP-1R). It consists of the GLP-1R agonist exendin-4 (a 39-amino acid peptide analog of GLP-1) conjugated to a chelator (such as NODAGA, NOTA, DOTA, or DO3A) and radiolabeled with the positron-emitting isotope gallium-68 (Ga-68). GLP-1R is highly expressed on pancreatic beta cells and overexpressed in benign insulinomas. Gallium Ga-68 exendin PET/CT imaging is used for the preoperative localization of insulinomas, the detection of focal congenital hyperinsulinism (CHI), and the noninvasive monitoring of pancreatic islet grafts in patients with type 1 diabetes.

Other names: 68Ga-DO3A-VS-Cys40-exendin-468Ga-DOTA-exendin-468Ga-NODAGA-exendin-468Ga-NOTA-exendin-468Ga-exendin68Ga-exendin-4[68Ga]Ga-DO3A-VS-Cys40-exendin-4[68Ga]Ga-DOTA-exendin-4[68Ga]Ga-NODAGA-exendin-4[68Ga]Ga-NOTA-exendin-4gallium Ga-68 DO3A-VS-Cys40-exendin-4gallium Ga-68 DOTA-exendin-4gallium Ga-68 NODAGA-exendin-4gallium Ga-68 NOTA-exendin-4

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on gallium Ga-68 exendin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium Ga-68 exendin.